Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Influenza and pneumococcal vaccine responses during lenalidomide treatment in multiple myeloma
NL-OMON40484Withdrawn
- Sponsor
- St. Antonius Ziekenhuis
- Start
- Jul 2014
- Modality
- Small Molecules, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label trial of lenalidomide, influenza vaccine and Prevnar 13 in multiple myeloma (MM) (2 arms), sponsored by St. Antonius Ziekenhuis. Primary endpoint: Primary: antibody response to influenza and pneumococcal vaccination. Planned start Jul 2014; status: withdrawn.
02
Drugs
lenalidomideinfluenza vaccinePrevnar 13
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON40484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40484.